Oruka Therapeutics, Inc.

NASDAQ:ORKA

Biotechnology

Healthcare
$96.32 +0.65%

+$0.46 today

Market cap
$6.53B
Beta
-0.30
P/E (TTM)
-33.9
EPS (TTM)
-$2.11
52W Low $10.77High $91.00

Volume 0.78M

Average 1.55M

Returns on capital

Oruka Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-22.3%

avg -57.2%

ROIC

-25.8%

avg -58.5%

ROA

-21.6%

avg -50.9%

Analysis

ROA is currently the strongest return metric at -21.6% versus its period average of -50.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Lawrence Otto Klein

President, Chief Executive Officer & DirectorUSD 1.08M43923.13K2.46%

Joana Goncalves

Chief Medical OfficerUSD 730.98K5231.77K0.08%

Paul T. Quinlan

General Counsel & SecretaryUSD 730.98K6330.00K0.08%

Alan Lada

VP of IR & Capital Markets————

Larry Todd Edwards

Chief Commercial Officer—630<0.01%

Laura Sandler

Chief Operating Officer—49——

Rajiv Panwar

Senior VP and Head of Chemistry, Manufacturing & Controls————

Arjun Agarwal

Senior Vice President of Finance & Treasurer—5014.22K0.04%

Christopher Finch

Senior VP and Head of Business Development & Strategy————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 12, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

115

$340.88M

Net Transaction Value

−$340.88M

Net selling

Most Active

Agarwal Arjun

35 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 12, 26

Agarwal Arjun

Direct

Sell$51K
Nov 12, 26

Agarwal Arjun

Direct

Sell$82.6K
Nov 12, 26

Agarwal Arjun

Direct

Sell$83.3K
Nov 12, 26

Agarwal Arjun

Direct

Sell$720.3K
Nov 12, 26

Agarwal Arjun

Direct

Sell$101.7K
Nov 12, 26

Agarwal Arjun

Direct

Sell$10.7K
Nov 12, 26

BALL KRISTINE M

Direct

Sell$122.1K
Nov 12, 26

BALL KRISTINE M

Direct

Sell$134K
Nov 12, 26

BALL KRISTINE M

Direct

Sell$212.4K
Nov 12, 26

BALL KRISTINE M

Direct

Sell$1.1M

1–10 of 115

Summary

Insiders reported 0 buys worth $0.00 and 115 sells worth $340.88M over the last 12 months. That adds up to net selling of $340.88M. Agarwal Arjun was the most active insider with 35 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A5 analysts
RevenueN/AN/AN/A
N/A3 analysts
Net IncomeN/AN/AN/A
N/A3 analysts
EBITN/AN/AN/A
N/A3 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Oruka Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about ORKA's management, answered from reported figures.

Who manages ORKA?

Oruka Therapeutics, Inc. (ORKA) lists 9 active executives. The top listed executive is Joana Goncalves, Chief Medical Officer.

Are ORKA insiders buying or selling?

Recent insider activity shows net selling of $338.83M.